TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
TapImmune has snapped up privately-owned Marker Therapeutics to create a new company based on a non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform.
TapImmune, the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies.
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc.